"Biological effects of soluble recombinant CD40 ligand and interferon-γ on human renal cancer cell lines in vitro and in vivo."

1. CD 40上人类renal cancer cell line的表面表达。免疫荧光研究通过流式细胞分析进行了性能分析。CD 40在各种人类癌症细胞线（769-P、786-O、A-498和A-704.2）上发表。CD 40通过干扰素-γ在体外表达的诱导.与干扰素-g在人类癌症细胞线上有意义地诱导的表面表达的诱导。溶剂重组CD 40环（srCD 40 L）和人体癌症细胞线上的抗原效应。用srCD 40 L明显抑制了769-P和786-O的增加，并通过测定测定与最佳抑制甲状腺素增加的优化。通过流动细胞计数学揭示了这两个细胞线中凋亡的一个定义。附加抑制剂效应由协同孵化与干扰-γ显著地增强了该抑制剂效应。在SCID mice bearing human renal cancer cell lines中的Antitumor effects of srCD40L treatment on surManagement in human renal cancer cell-bearing SCID mice were determined。所有老鼠都接受了20微升的抗asialo GMI （大Wako Chemicals），由内向注射（IV） 1天前移植到移除宿主自然杀手细胞。769-P细胞（5xl 0-D16-D1）由IV管理。SCID recipients then received either l0/g of srCD 40 L或控制每一天20天的总10个injections starting at day 3。吃肿瘤的老鼠然后被监测到肿瘤的发展和进步。用srCD 40 L有效地改善了接受肿瘤老鼠的生存（p<0.05）。我们将从日本癌症研究杂志的这些数据中准备一份手稿。

1. Surface expression of CD40 on human renal cancer cell line.Immunofluorescence studies were performed by flow cytometric analysis. CD40 was expressed on various human renal cancer cell lines, 769-P, 786-O, A-498 and A-704.2. Induction of CD40 expression by interferon-γ in vitro.Incubation with interferon-g significantly induced surface expression on human renal cancer cell lines.3. Antitumor effects of soluble recombinant CD40 lingand (srCD40L) and interferon-γ on human renal cancer cell lines in vitro.Incubation with srCD40L significantly inhibited the proliferation of 769-P and 786-O as determined by the proliferation assay with optimal inhibition of thymidine incorporation. Apoptotic studies by flow cytometry revealed an induction of apoptosis in these two cell lines. Additional inhibitory effect by co-incubation with interfron-γ significantly enhanced this inhibitory effects.4. Antitumor effects of srCD40L treatment in SCID mice bearing human human renal cancer cell lines.Effects of srCD40L treatment on survival in human renal cancer cell-bearing SCID mice were determined. All mice received 20 μL of anti-asialo GMI (Wako Chemicals, Osaka) by intravenous injection (IV) 1 day before tumor transfer to remove host natural killer cells. 769-P cells (5 x l0ィイD16ィエD1) were then administered by IV. SCID recipients then received either l0 μg of srCD40L or controll every other day for 20 days for total of 10 injections starting at day 3. Tumor bearing mice were then monitored for tumor development and progression. Treatment with srCD40L significantly improved the survival of tumor-bearing mice (p<0.05).We are preparing a manuscript from these data for Japanese Journal for Cancer Research.